0113 392 6818
Summary: Professor of Medical Microbiology
Location: Microbiology, Old Medical School, Leeds General Infirmary
Teaching Commitments: Lectures to undergraduate students in Medicine, Dentistry, and Science (Microbiology).
Professor Mark Wilcox is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Molecular Medicine), and is the Lead on Clostridium difficile for the Public Health England (PHE). He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years) and Clinical Director of Pathology (6 years) at LTHT.
Professor Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and is a member of the HPA’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. He is an advisor to the Department of Health in England on healthcare associated infections (HCAIs), the Technology Strategy Board on HCAI diagnostics, the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust on novel antimicrobials, and the European Centre for Disease Control. He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of the Journal of Hospital infection and Infectious Diseases in Clinical Practice. He has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents.
Professor Wilcox’s research team’s projects include several areas of healthcare associated infection, in particular Clostridium difficile infection, staphylococcal infection, and the clinical development of new antimicrobial agents. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for 12 clinical trials of new anti-infective drugs, 1999-2010, is currently supplying central laboratory services for 4 clinical trials of antimicrobial agents, and is carrying out multiple NIHR portfolio studies on healthcare associated infection topics. He has authored more than 320 papers and published a number of books and chapters. He is co-editor of Antimicrobial Chemotherapy (5th & 6th Eds, 2007 & 2012).